

Coming soon HCI-030 PDX

Catalogue number: 162095

Sub-type:

Images:

Contributor

Inventor: Alana L Welm, Yi-Chun Lin, Yoko Sakata DeRose

Institute: The University of Utah Research Foundation

Images:

Tool details

***FOR RESEARCH USE ONLY**

Name: Coming soon HCI-030 PDX

Alternate name:

Class:

Conjugate:

Description: Please register your interest through the enquiry button (quote not currently available)
Human breast cancer-derived xenograft that retains high fidelity to original tumour and provides valuable resources for drug discovery and precision oncology. This panel of Patient Derived Xenografts provide models for some of the deadliest forms of breast cancer including drug-resistant, metastatic tumours, and endocrine-resistant estrogen receptor-positive (ER+) and HER2+ tumours. Sample collected in 2010 from breast tumour recurrence of Caucasian female, age 57 at time of collection with a primary diagnosis of poorly differentiated carcinoma 1999. Patient was a former smoker for 48 years, and had no clinical metastasis detected. Patient had undergone radiation therapy of breast in 1999 and had received systemic treatment of chemotherapy of unknown type 1999-2002 prior to sample collection. Patient and PDX characteristics were as follows - ER status: negative, PR status: negative, HER2 status: negative. PDX information: PAM50 subtype is basal-like and metastasis in lung, detected.

Purpose:

Parental cell:

Organism:

Tissue:

Model:

Gender: Female

Isotype:

Reactivity:

Selectivity:

Host:

Immunogen:

Immunogen UNIPROT ID:

Sequence:

Growth properties:

Production details: Fresh or thawed human breast tumour fragments were implanted into the cleared inguinal mammary fat pad of female Immune-compromised mice. For bone metastasis samples, bone fragments were coimplanted. For liquid specimens, pleural effusion, or ascites fluid, 1-2 milion cells were injected into cleared mammary fat pads in Matrigel. For ER+ tumours, mice were dosed with E2 beeswax pellets and given supplemental E2 via drinking water. When tumours reached 1-2 cm in diameter, tumours were aseptically collected and reimplanted into new m ice or banked. Estrogen-independent ER+ breast PDX models were generated when ER+ PDX tumours were transplated into overiectomized mice without E2 supplementation.

Formulation: Frozen explant from the xenografted tumour

Recommended controls:

Bacterial resistance:

Selectable markers:

Additional notes: Additional Information on PDX establishment:

<https://www.nature.com/articles/s43018-022-00337-6/figures/9>

Target details

Target:

Target alternate names:

Target background:

Molecular weight:

Ic50:

Applications

Application:

Application notes:

Handling

Format:

Concentration:

Passage number:

Growth medium:

Temperature:

Atmosphere:

Volume:

Storage medium:
Storage buffer:
Storage conditions:
Shipping conditions:

Related tools

Related tools:

References

References:

CancerTools.org